Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
FDA accepted United Therapeutics' NDA for ralinepag to treat pulmonary arterial hypertension (PAH), setting a PDUFA target action date of June 24, 2027.
USA Rare Earth completed a $1.55 billion capitalization of a special purpose vehicle (SPV) for Serra Verde offtake, up from the originally planned $1.3 billion.
European Commission approves Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for first-line metastatic triple-negative breast cancer (TNBC) with PD-L1 CPS ≥10.
